Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

764 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
Effects of Pembrolizumab in Recurrent/Metastatic Squamous Cell Head and Neck Carcinoma: A Multicenter Retrospective Study.
Okada T, Fushimi C, Matsuki T, Tokashiki K, Takahashi H, Okamoto I, Sato H, Kondo T, Hanyu K, Kishida T, Ito T, Yamashita G, Masubuchi T, Tada Y, Miura K, Omura GO, Yamashita T, Oridate N, Tsukahara K. Okada T, et al. Among authors: kishida t. Anticancer Res. 2023 Jun;43(6):2717-2724. doi: 10.21873/anticanres.16438. Anticancer Res. 2023. PMID: 37247908
Laryngeal Cancer With Lung Metastases Showing Long-Term Complete Response and Delayed Immune-Related Adverse Event After Nivolumab Discontinuation.
Kondo T, Nakatsugawa M, Okubo M, Nakamura H, Yunaiyama D, Wakiya M, Takeda A, Kikawada N, Kishida T, Someya M, Yoshida S, Ogawa Y, Tsukahara K. Kondo T, et al. Among authors: kishida t. Ear Nose Throat J. 2021 Jul 19:1455613211031025. doi: 10.1177/01455613211031025. Online ahead of print. Ear Nose Throat J. 2021. PMID: 34281424 Free article.
Comparison of Dosage of Nivolumab in Efficacy and Safety for Recurrent Metastatic Squamous Cell Carcinoma.
Okada T, Fushimi C, Matsuki T, Okamoto I, Sato H, Kondo T, Tokashiki K, Kishida T, Ito T, Yamashita G, Aihara Y, Hanyu K, Kushihashi Y, Masubuchi T, Tada Y, Miura K, Harada Y, Momiyama K, Yamashita T, Omura GO, Takahashi H, Oridate N, Tsukahara K. Okada T, et al. Among authors: kishida t. Anticancer Res. 2022 Mar;42(3):1607-1613. doi: 10.21873/anticanres.15635. Anticancer Res. 2022. PMID: 35220258
Tracheobronchial chondritis as an immune-related adverse event occurring during the administration of nivolumab for recurrent hypopharyngeal squamous cell carcinoma.
Someya M, Kondo T, Okimura A, Nakatsugawa M, Okubo M, Yunaiyama D, Takeda A, Kishida T, Yoshida S, Yonekura M, Ogawa Y, Tsukahara K. Someya M, et al. Among authors: kishida t. Ear Nose Throat J. 2022 Mar 27:1455613221081912. doi: 10.1177/01455613221081912. Online ahead of print. Ear Nose Throat J. 2022. PMID: 35343278 Free article.
Retroperitoneal low-grade fibromyxoid sarcoma.
Noguchi T, Suzuki T, Shibata Y, Koizumi M, Osaka K, Kishida T. Noguchi T, et al. Among authors: kishida t. IJU Case Rep. 2024 Mar 3;7(3):255-258. doi: 10.1002/iju5.12718. eCollection 2024 May. IJU Case Rep. 2024. PMID: 38686065 Free PMC article.
MMP1, IL-1β, sTNFR-1, and IL-6 are prognostic factors for patients with unresectable or metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Nagasaka H, Kishida T, Kouro T, Igarashi Y, Takebe S, Yamamoto S, Kondo T, Koizumi M, Terao H, Suzuki T, Nakaigawa N, Himuro H, Wei F, Sasada T. Nagasaka H, et al. Among authors: kishida t. Int J Clin Oncol. 2024 Apr 6. doi: 10.1007/s10147-024-02477-4. Online ahead of print. Int J Clin Oncol. 2024. PMID: 38580797
764 results